MedTrace Logo

ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP)

NCT02502240 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 7000

Last updated 2017-03-03

No results posted yet for this study

Summary

Evaluation of the frequency and clinical characteristics of ALK rearrangements in Latin-American countries.

Latin American countries are heterogeneous in terms of lung cancer incidence, ethnicity, and exposure to potential carcinogens. The discovery of the echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) translocation as an oncogenic driver has led to the development of novel therapies with activity in vitro and in the clinic.

Conditions

Sponsors & Collaborators

  • Instituto Nacional de Cancerologia de Mexico

    lead OTHER

Principal Investigators

  • Oscar Gerardo Arrieta Rodriguez, MD MSc · Instituto Nacional de Cancerología Mexico city

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02502240 on ClinicalTrials.gov